Max Seidensticker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9596274/publications.pdf

Version: 2024-02-01

201575 175177 3,109 122 27 52 citations h-index g-index papers 126 126 126 3357 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. Journal of Cancer Research and Clinical Oncology, 2022, 148, 475-485.	1.2	13
2	Advances in Diagnostic and Interventional Radiology in Hepatocellular Carcinoma. Digestive Diseases, 2022, 40, 458-467.	0.8	4
3	Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial. European Radiology, 2022, 32, 1320-1329.	2.3	5
4	Stent-graft placement for hepatic arterial bleeding: assessment of technical efficacy and clinical outcome in a tertiary care center. Hpb, 2022, 24, 672-680.	0.1	4
5	Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma. British Journal of Cancer, 2022, 126, 211-218.	2.9	18
6	Current State of Multidisciplinary Treatment in Cholangiocarcinoma. Digestive Diseases, 2022, 40, 581-595.	0.8	7
7	Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncology, 2022, 18, 1423-1435.	1.1	14
8	Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only—A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort. Current Oncology, 2022, 29, 565-577.	0.9	O
9	Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib. Cancer Imaging, 2022, 22, 1.	1.2	11
10	Interventional recanalization therapy in patients with non-cirrhotic, non-malignant portal vein thrombosis: comparison between transjugular versus transhepatic access. Abdominal Radiology, 2022, 47, 1177-1186.	1.0	4
11	Reply. Liver Transplantation, 2022, 28, 897-898.	1.3	O
12	Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: The DEMAND randomized phase II clinical trial Journal of Clinical Oncology, 2022, 40, TPS492-TPS492.	0.8	O
13	Semi-Automatic MRI Feature Assessment in Small- and Medium-Volume Benign Prostatic Hyperplasia after Prostatic Artery Embolization. Diagnostics, 2022, 12, 585.	1.3	1
14	Extrahepatic Disease in Hepatocellular Carcinoma: Do We Always Need Whole-Body CT or Is Liver MRI Sufficient? A Subanalysis of the SORAMIC Trial. Biomedicines, 2022, 10, 1156.	1.4	0
15	Correlation of chemokines and growth factors with radiation-induced liver injury after interstitial high dose rate (HDR) brachytherapy of liver metastases. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2815-2826.	1.2	2
16	Image-Guided Embolotherapy of Arteriovenous Malformations of the Face. CardioVascular and Interventional Radiology, 2022, 45, 992-1000.	0.9	8
17	Ablation of Liver Metastases byÂBrachytherapy. , 2021, , 105-115.		O
18	Liver Function Changes After Technetium-99m-Macroaggregated Albumin Administration and Their Predictive Value Regarding Hepatotoxicity in Patients Undergoing Yttrium-90-Radioembolization. Anticancer Research, 2021, 41, 437-444.	0.5	1

#	Article	IF	Citations
19	Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis. Cancers, 2021, 13, 521.	1.7	5
20	Liver transplantation versus watchful waiting in hepatocellular carcinoma patients with complete response to bridging therapy – a retrospective observational study. Transplant International, 2021, 34, 465-473.	0.8	4
21	Cost-Effectiveness Analysis of Local Ablation and Surgery for Liver Metastases of Oligometastatic Colorectal Cancer. Cancers, 2021, 13, 1507.	1.7	15
22	iRESCUE – Interventional embolization of Renal artEries after SurgiCal or traUmatic injury with hEmorrhage. European Journal of Radiology, 2021, 136, 109540.	1.2	5
23	Impact of Pharmaceutical Prophylaxis on Radiation-Induced Liver Disease Following Radioembolization. Cancers, 2021, 13, 1992.	1.7	7
24	Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma. Radiation Oncology, 2021, 16, 86.	1.2	11
25	Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease. Frontiers in Oncology, 2021, 11, 667993.	1.3	4
26	Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization. EJNMMI Research, 2021, 11, 51.	1.1	7
27	Extending the Use of Atezolizumab and Bevacizumab to a Liver Transplant Recipient: Need for a Posttransplant Registry. Liver Transplantation, 2021, 27, 928-929.	1.3	11
28	Validation of the collapsed cone algorithm for HDR liver brachytherapy against Monte Carlo simulations. Brachytherapy, 2021, 20, 936-947.	0.2	1
29	Percutaneous Sclerotherapy of Venous Malformations of the Hand: A Multicenter Analysis. CardioVascular and Interventional Radiology, 2021, 44, 1543-1550.	0.9	14
30	Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma. Journal of Hepatology, 2021, 75, 1387-1396.	1.8	22
31	Bi-Centric Independent Validation of Outcome Prediction after Radioembolization of Primary and Secondary Liver Cancer. Journal of Clinical Medicine, 2021, 10, 3668.	1.0	1
32	HDR Brachytherapy and SBRT as Bridging Therapy to Liver Transplantation in HCC Patients: A Single-Center Experience. Frontiers in Oncology, 2021, 11, 717792.	1.3	8
33	Reproducibility of CT-Based Hepatocellular Carcinoma Radiomic Features across Different Contrast Imaging Phases: A Proof of Concept on SORAMIC Trial Data. Cancers, 2021, 13, 4638.	1.7	8
34	Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	3
35	Lower Ratio of Liver Volume and Body Weight Is a Negative Predictor of Survival after Transjugular Intrahepatic Portosystemic Shunt. Journal of Personalized Medicine, 2021, 11, 903.	1.1	2
36	The Impact of Unilateral 90Y-radioembolization on Functional Changes in the Contralateral Hepatic Lobe. Annals of Surgery Open, 2021, 2, e095.	0.7	5

#	Article	IF	Citations
37	Combined Transarterial Embolization and Percutaneous Sclerotherapy as Treatment for Refractory and Nonresectable Aneurysmal Bone Cysts. Journal of Vascular and Interventional Radiology, 2021, 32, 1425-1434.e2.	0.2	8
38	Multispectral optoacoustic tomography of peripheral arterial disease based on muscle hemoglobin gradientsâ€"a pilot clinical study. Annals of Translational Medicine, 2021, 9, 36-36.	0.7	23
39	Artifact reduction of coaxial needles in magnetic resonance imaging-guided abdominal interventions at 1.5 T: a phantom study. Scientific Reports, 2021, 11, 22963.	1.6	2
40	Image-Guided Local Treatment for Unresectable Intrahepatic Cholangiocarcinoma—Role of Interventional Radiology. Journal of Clinical Medicine, 2021, 10, 5574.	1.0	3
41	Interstitial High-Dose-Rate Brachytherapy of Liver Metastases in Oligometastatic Patients. Cancers, 2021, 13, 6250.	1.7	6
42	Liver Transplantation for Extended Criteria Hepatocellular Carcinoma Using Stable Response to Locoregional Therapy and Alpha-Fetoprotein as Selection Criteria. Visceral Medicine, 2020, 36, 506-515.	0.5	7
43	Reply to: "Toxicity and dosimetry in SORAMIC study― Journal of Hepatology, 2020, 73, 735-736.	1.8	0
44	Radioembolization for neuroendocrine liver metastases is safe and effective prior to major hepatic resection. Hepatobiliary Surgery and Nutrition, 2020, 9, 312-321.	0.7	4
45	Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. JHEP Reports, 2020, 2, 100173.	2.6	24
46	Therapeutic Concepts for Oligometastatic Gastrointestinal Tumours. Visceral Medicine, 2020, 36, 359-363.	0.5	2
47	Interstitial Brachytherapy for Limited (<4 cm) and Large (≥4 cm) Hepatic Metastases from Rare and Less Common Cancers. Anticancer Research, 2020, 40, 4281-4289.	0.5	4
48	3D image-based dosimetry for Yttrium-90 radioembolization of hepatocellular carcinoma: Impact of imaging method on absorbed dose estimates. Physica Medica, 2020, 80, 317-326.	0.4	15
49	Multi-modal and sequential treatment of liver cancer and its impact on the gastrointestinal tract. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2020, 48-49, 101709.	1.0	2
50	The Impact of Glucocorticoid Co-Secretion in Primary Aldosteronism on Thyroid Autoantibody Titers During the Course of Disease. Hormone and Metabolic Research, 2020, 52, 404-411.	0.7	6
51	Transarterial embolization of acute iatrogenic hemorrhages: predictive factors for mortality and outcome. British Journal of Radiology, 2020, 93, 20190413.	1.0	4
52	The dosimetric impact of replacing the TG-43 algorithm by model based dose calculation for liver brachytherapy. Radiation Oncology, 2020, 15, 60.	1.2	10
53	Posterior Reversible Encephalopathy Syndrome After 90Y-Resin Microspheres Radioembolization. Clinical Nuclear Medicine, 2020, 45, 202-203.	0.7	0
54	The Effect of Biochemical Remission on Bone Metabolism in Cushing's Syndrome: A 2â€Year Followâ€Up Study. Journal of Bone and Mineral Research, 2020, 35, 1711-1717.	3.1	20

#	Article	IF	CITATIONS
55	Impact of Extrahepatic Metastases on Overall Survival in Patients with Advanced Liver Dominant Hepatocellular Carcinoma: A Subanalysis of the SORAMIC Trial. Liver Cancer, 2020, 9, 771-786.	4.2	17
56	Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. Journal of Hepatology, 2019, 71, 1164-1174.	1.8	249
57	Evaluation of proton and photon dose distributions recalculated on 2D and 3D Unet-generated pseudoCTs from T1-weighted MR head scans. Acta Oncológica, 2019, 58, 1429-1434.	0.8	33
58	FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). Journal of Clinical Oncology, 2019, 37, 3401-3411.	0.8	132
59	Adrenal Insufficiency After Unilateral Adrenalectomy in Primary Aldosteronism: Long-Term Outcome and Clinical Impact. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5658-5664.	1.8	37
60	Treatment of hepatic pancreatic ductal adenocarcinoma metastases with high-dose-rate image-guided interstitial brachytherapy: a single center experience. Journal of Contemporary Brachytherapy, 2019, 11, 329-336.	0.4	5
61	Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. Journal of Translational Medicine, 2019, 17, 328.	1.8	51
62	First report on extended distance between tumor lesion and adjacent organs at risk using interventionally applied balloon catheters: a simple procedure to optimize clinical target volume covering effective isodose in interstitial high-dose-rate brachytherapy of liver malignomas. Journal of Contemporary Brachytherapy, 2019, 11, 152-161.	0.4	12
63	Radioablation of Hepatic Metastases from Renal Cell Carcinoma With Image-guided Interstitial Brachytherapy. Anticancer Research, 2019, 39, 2501-2508.	0.5	7
64	Efficacy and safety of CT-guided high-dose-rate interstitial brachytherapy in primary and secondary malignancies of the pancreas. European Journal of Radiology, 2019, 112, 22-27.	1.2	3
65	Biliary duct stenosis after image-guided high-dose-rate interstitial brachytherapy of central and hilar liver tumors. Strahlentherapie Und Onkologie, 2019, 195, 265-273.	1.0	10
66	Treatment of metastatic, imatinib refractory, gastrointestinal stroma tumor with image-guided high-dose-rate interstitial brachytherapy. Brachytherapy, 2019, 18, 63-70.	0.2	7
67	Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial. CardioVascular and Interventional Radiology, 2019, 42, 239-249.	0.9	31
68	Angiographic Anatomy and Relevance of 3 and 9 O'clock Arteries During Radioembolization. CardioVascular and Interventional Radiology, 2018, 41, 890-897.	0.9	1
69	Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection. Digestion, 2018, 98, 69-74.	1.2	5
70	Needle track seeding in hepatocellular carcinoma after local ablation by high-dose-rate brachytherapy: a retrospective study of 588 catheter placements. Journal of Contemporary Brachytherapy, 2018, 10, 516-521.	0.4	10
71	Image-guided interstitial high-dose-rate brachytherapy in the treatment of metastatic esophageal squamous cell carcinoma. Journal of Contemporary Brachytherapy, 2018, 10, 439-445.	0.4	3
72	Image-guided Interstitial Brachytherapy in the Management of Metastasized Anal Squamous Cell Carcinoma. Anticancer Research, 2018, 38, 5401-5407.	0.5	4

#	Article	IF	Citations
73	Local ablation or radioembolization of colorectal cancer metastases: comorbidities or older age do not affect overall survival. BMC Cancer, 2018, 18, 882.	1.1	18
74	Transcatheter arterial embolization of acute bleeding as 24/7 service: predictors of outcome and mortality. British Journal of Radiology, 2018, 91, 20180516.	1.0	8
75	Cytokines and 90Y-Radioembolization: Relation to Liver Function and Overall Survival. CardioVascular and Interventional Radiology, 2017, 40, 1185-1195.	0.9	27
76	Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro. Anticancer Research, 2017, 37, 87-94.	0.5	11
77	Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma. Gastroenterology Research and Practice, 2016, 2016, 1-13.	0.7	27
78	Modified transarterial chemoembolization with locoregional administration of sorafenib for treating hepatocellular carcinoma: feasibility, efficacy, and safety in the VX-2 rabbit liver tumor model. Diagnostic and Interventional Radiology, 2016, 22, 378-384.	0.7	7
79	Improvement of Contrast Media Enhancement in CTA Evaluating Pulmonary Embolism by Utilizing †Delayed' Bolus Tracking in the Descending Aorta. Polski Przeglad Radiologii I Medycyny Nuklearnej, 2016, 81, 422-427.	1.0	4
80	Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system. BMC Cancer, 2016, 16, 509.	1.1	30
81	Radioablation of liver malignancies with interstitial high-dose-rate brachytherapy. Strahlentherapie Und Onkologie, 2016, 192, 288-296.	1.0	34
82	Haemorrhagic Complications and Symptomatic Venous Thromboembolism in Interventional Tumour Ablations: The Impact of Peri-interventional Thrombosis Prophylaxis. CardioVascular and Interventional Radiology, 2016, 39, 1716-1721.	0.9	16
83	Molecular imaging and liver function assessment by hepatobiliary MRI. Journal of Hepatology, 2016, 65, 1081-1082.	1.8	5
84	Integration of chemoembolization and radioembolization into multimodal treatment of cholangiocarcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 319-332.	1.0	24
85	Prophylactic Embolization of the Cystic Artery Prior to Radioembolization of Liver Malignancies—An Evaluation of Necessity. CardioVascular and Interventional Radiology, 2015, 38, 678-684.	0.9	19
86	Time-Resolved Perfusion Imaging at the Angiography Suite. Investigative Radiology, 2015, 50, 108-113.	3.5	5
87	Hybrid SPECT/CT for the assessment of a painful hip after uncemented total hip arthroplasty. BMC Medical Imaging, 2015, 15, 18.	1.4	40
88	Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study). BMC Cancer, 2015, 15, 517.	1.1	11
89	Radiation-Induced Liver Damage: Correlation of Histopathology with Hepatobiliary Magnetic Resonance Imaging, a Feasibility Study. CardioVascular and Interventional Radiology, 2015, 38, 213-221.	0.9	25
90	Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology, 2014, 59, 1864-1873.	3.6	133

#	Article	IF	Citations
91	Safety of Repeated Radioembolizations in Patients with Advanced Primary and Secondary Liver Tumors and Progressive Disease After First Selective Internal Radiotherapy. Journal of Nuclear Medicine, 2014, 55, 360-366.	2.8	33
92	Prospective Randomized Trial of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid for Prevention of Radiation-Induced Liver Toxicity. PLoS ONE, 2014, 9, e112731.	1.1	46
93	Retroperitoneoscopic and laparoscopic removal of periadrenally located bronchogenic cysts – aÂsystematic review. Polski Przeglad Chirurgiczny, 2013, 85, 706-13.	0.2	7
94	When Inoperable Becomes Operable?. Journal of Clinical Oncology, 2013, 31, 4474-4474.	0.8	1
95	Estimation of return-to-sports-time for athletes with stress fracture – an approach combining risk level of fracture site with severity based on imaging. BMC Musculoskeletal Disorders, 2012, 13, 139.	0.8	40
96	Matched-Pair Comparison of Radioembolization Plus Best Supportive Care Versus Best Supportive Care Alone for Chemotherapy Refractory Liver-Dominant Colorectal Metastases. CardioVascular and Interventional Radiology, 2012, 35, 1066-1073.	0.9	137
97	Hepatic Toxicity After Radioembolization of the Liver Using 90Y-Microspheres: Sequential Lobar Versus Whole Liver Approach. CardioVascular and Interventional Radiology, 2012, 35, 1109-1118.	0.9	74
98	Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy – A phase II-study. Radiotherapy and Oncology, 2011, 100, 314-319.	0.3	55
99	Wound Microenvironment Sequesters Adipose-Derived Stem Cells in a Murine Model of Reconstructive Surgery in the Setting of Concurrent Distant Malignancy. Plastic and Reconstructive Surgery, 2011, 127, 1467-1477.	0.7	19
100	Tracking Long-Term Survival of Intramyocardially Delivered Human Adipose Tissue-Derived Stem Cells Using Bioluminescence Imaging. Molecular Imaging and Biology, 2011, 13, 633-645.	1.3	57
101	Advantages and Disadvantages of the Amplatzer Vascular Plug IV in Visceral Embolization: Report of 50 Placements. CardioVascular and Interventional Radiology, 2011, 34, 1069-1073.	0.9	12
102	In vivo assessment of catheter positioning accuracy and prolonged irradiation time on liver tolerance dose after single-fraction 192Ir high-dose-rate brachytherapy. Radiation Oncology, 2011, 6, 107.	1.2	8
103	Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes. Radiation Oncology, 2011, 6, 40.	1.2	49
104	Assessment of fast dynamic imaging and the use of Gdâ€EOBâ€DTPA for MRâ€guided liver interventions. Journal of Magnetic Resonance Imaging, 2011, 34, 874-879.	1.9	12
105	Human Tissue-Resident Stem Cells Combined with Hyaluronic Acid Gel Provide Fibrovascular-Integrated Soft-Tissue Augmentation in a Murine Photoaged Skin Model. Plastic and Reconstructive Surgery, 2010, 125, 63-73.	0.7	38
106	Computed Tomography–Guided High-Dose-Rate Brachytherapy in Hepatocellular Carcinoma: Safety, Efficacy, and Effect on Survival. International Journal of Radiation Oncology Biology Physics, 2010, 78, 172-179.	0.4	111
107	Local Response and Impact on Survival After Local Ablation of Liver Metastases From Colorectal Carcinoma by Computed Tomography–Guided High-Dose-Rate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 479-485.	0.4	124
108	Safety margin in irradiation of colorectal liver metastases: assessment of the control dose of micrometastases. Radiation Oncology, 2010, 5, 24.	1.2	15

#	Article	IF	CITATIONS
109	Radiobiological restrictions and tolerance doses of repeated single-fraction hdr-irradiation of intersecting small liver volumes for recurrent hepatic metastases. Radiation Oncology, 2010, 5, 44.	1.2	31
110	Both cultured and freshly isolated adipose tissue-derived stem cells enhance cardiac function after acute myocardial infarction. European Heart Journal, 2010, 31, 489-501.	1.0	201
111	Image-Guided Interstitial High-Dose-Rate Brachytherapy in Hepatocellular Carcinoma. Digestive Diseases, 2009, 27, 170-174.	0.8	19
112	Phase II Feasibility Study on the Combination of Two Different Regional Treatment Approaches in Patients with Colorectal "Liver-Only―Metastases: Hepatic Interstitial Brachytherapy Plus Regional Chemotherapy. CardioVascular and Interventional Radiology, 2009, 32, 937-945.	0.9	18
113	Hepatocellular Carcinoma and Liver Cirrhosis: Assessment of the Liver Function after Yttrium-90 Radioembolization with Resin Microspheres or after CT-Guided High-Dose-Rate Brachytherapy. Digestive Diseases, 2009, 27, 189-199.	0.8	18
114	In VivoAssessment of Dose Volume and Dose Gradient Effects on the Tolerance Dose of Small Liver Volumes after Single-Fraction High-Dose-Rate 1921r Irradiation. Radiation Research, 2009, 172, 598-606.	0.7	16
115	Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis, 2009, 30, 589-597.	1.3	296
116	CT-Guided Brachytherapy (CTGB) versus Interstitial Laser Ablation (ILT) of Colorectal Liver Metastases. Strahlentherapie Und Onkologie, 2008, 184, 302-306.	1.0	27
117	Radiotherapy of Liver Metastases. Strahlentherapie Und Onkologie, 2008, 184, 256-261.	1.0	39
118	Assessment of the tolerance dose of the hepatic reticulo-endothelial system (RES) after single fraction HDR-irradiation: An <i>in-vivo</i> study employing SSPIO. International Journal of Radiation Biology, 2008, 84, 830-837.	1.0	1
119	Minimal invasive Onkologie in der Therapie von Lebermetastasen. Chirurgische Gastroenterologie Interdisziplinar, 2008, 24, 207-215.	0.0	0
120	In vivo assessment of the tolerance dose of small liver volumes after single-fraction HDR irradiation. International Journal of Radiation Oncology Biology Physics, 2005, 62, 776-784.	0.4	59
121	Liver Malignancies: CT-Guided Interstitial Brachytherapy in Patients with Unfavorable Lesions for Thermal Ablation. Journal of Vascular and Interventional Radiology, 2004, 15, 1279-1286.	0.2	110
122	Dynamics in Circulating y -55Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC $\hat{a} \in A$ Substudy From the SORAMIC Trial., 0, 1, .		0